Table I.
Expression of SSTR subtypes in primary breast tumor tissues.
| Clinical index | No. of cases | SSTR1+ (%) | SSTR2+ (%) | SSTR3+ (%) | SSTR4+ (%) | SSTR5+ (%) |
|---|---|---|---|---|---|---|
| Age, years | ||||||
| <40 | 23 | 21 (91.3) | 8 (34.8) | 9 (39.1) | 18 (78.3) | 12 (52.2) |
| >40 | 137 | 123 (89.8) | 47 (34.3) | 58 (42.3) | 96 (70.1) | 59 (43.1) |
| Cancer cell differentiationa | ||||||
| Poor | 83 | 79 (95.2) | 30 (36.1) | 39 (47.0) | 59 (71.1) | 37 (44.6) |
| Moderate | 54 | 47 (87.0) | 18 (33.3) | 20 (37.0) | 43 (79.6) | 26 (48.1) |
| Well | 23 | 18 (78.3)b | 7 (30.4) | 8 (34.8) | 12 (52.2)b | 8 (34.8) |
| Total | 160 | 144 (90.0) | 55 (34.4) | 67 (41.9) | 114 (71.3) | 71 (44.4) |
a
Cancer cell differentiation was evaluated according to the Scarff-Bloom-Richardson system recommended by World Health Organization.
b
P<0.05. SSTR, somatostatin receptor.